Published in Nat Med on December 01, 1996
Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol (2002) 5.75
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J (1997) 4.28
Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med (1998) 3.72
Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer (2009) 3.45
p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med (1998) 2.91
Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature (2009) 2.54
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res (2009) 2.51
Apoptosis: a mechanism of acute and chronic liver injury. Gut (2005) 2.33
Hepatocyte death: a clear and present danger. Physiol Rev (2010) 2.18
Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer (2006) 2.09
Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med (1997) 1.96
Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis. J Clin Invest (1998) 1.86
Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med (1999) 1.76
The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer (1998) 1.75
Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut (1999) 1.75
Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas. EMBO J (1999) 1.73
Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci U S A (1997) 1.69
Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci U S A (1997) 1.68
Suppression of Akt signaling induces Fas ligand expression: involvement of caspase and Jun kinase activation in Akt-mediated Fas ligand regulation. Mol Cell Biol (2002) 1.67
Induction of Fas ligand expression by HIV involves the interaction of Nef with the T cell receptor zeta chain. J Exp Med (1999) 1.63
Role of apoptosis in disease. Aging (Albany NY) (2012) 1.58
Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med (2000) 1.56
Polymorphism of murine Fas ligand that affects the biological activity. Proc Natl Acad Sci U S A (1997) 1.56
Ultraviolet radiation triggers apoptosis of fibroblasts and skin keratinocytes mainly via the BH3-only protein Noxa. J Cell Biol (2007) 1.53
Evasion of cytotoxic T lymphocyte (CTL) responses by nef-dependent induction of Fas ligand (CD95L) expression on simian immunodeficiency virus-infected cells. J Exp Med (1997) 1.52
CD95/CD95L-mediated apoptosis of the hepatic stellate cell. A mechanism terminating uncontrolled hepatic stellate cell proliferation during hepatic tissue repair. Am J Pathol (1997) 1.51
Cyclosporin A-sensitive transcription factor Egr-3 regulates Fas ligand expression. Mol Cell Biol (1998) 1.36
Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood (2005) 1.36
Antitumor immunity and cancer stem cells. Ann N Y Acad Sci (2009) 1.36
TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med (1998) 1.34
Immune evasion by murine melanoma mediated through CC chemokine receptor-10. J Exp Med (2003) 1.34
Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia (2002) 1.33
Regulation of the metastatic cell phenotype by sialylated glycans. Cancer Metastasis Rev (2012) 1.32
IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest (2001) 1.30
Fas/Fas ligand interaction in human colorectal hepatic metastases: A mechanism of hepatocyte destruction to facilitate local tumor invasion. Am J Pathol (1999) 1.25
Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. Gut (2006) 1.24
Oxidized LDL activates fas-mediated endothelial cell apoptosis. J Clin Invest (1998) 1.23
Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Invest (1998) 1.22
Apoptosis as a mechanism for liver disease progression. Semin Liver Dis (2010) 1.21
Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer (2001) 1.21
Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res (2006) 1.21
Tumour-induced apoptosis in human mesothelial cells: a mechanism of peritoneal invasion by Fas Ligand/Fas interaction. Br J Cancer (2004) 1.20
Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells. J Biol Chem (2011) 1.19
Roles of Fas and Fas ligand during mammary gland remodeling. J Clin Invest (2000) 1.18
T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. Mol Ther (2010) 1.17
Stimulation of CD95 (Fas) blocks T lymphocyte calcium channels through sphingomyelinase and sphingolipids. Proc Natl Acad Sci U S A (1999) 1.15
Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J Clin Invest (1997) 1.15
Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer (2002) 1.14
c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med (2004) 1.12
Inhibition of mitogen-activated kinase signaling sensitizes HeLa cells to Fas receptor-mediated apoptosis. Mol Cell Biol (1999) 1.11
Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. J Exp Med (1999) 1.10
Fas ligand upregulation is an early event in colonic carcinogenesis. J Clin Pathol (2001) 1.07
FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer (1999) 1.06
Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells. Blood (2007) 1.01
The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol Med (1997) 0.99
The immunoregulatory mechanisms of carcinoma for its survival and development. J Exp Clin Cancer Res (2011) 0.99
Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin Exp Immunol (1998) 0.98
Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege. Clin Diagn Lab Immunol (1999) 0.97
Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. Proc Natl Acad Sci U S A (1998) 0.97
Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer. Ann Surg (1997) 0.97
T cell-tumor cell: a fatal interaction? Cancer Immunol Immunother (1998) 0.97
Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br J Cancer (2000) 0.96
The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br J Cancer (2000) 0.95
Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer. Br J Cancer (2001) 0.95
Hodgkin disease and the role of the immune system. Pediatr Hematol Oncol (2011) 0.95
The prognostic value of the apoptosis pathway in colorectal cancer: a review of the literature on biomarkers identified by immunohistochemistry. Biomark Cancer (2013) 0.94
Increased expression of Fas ligand on Mycobacterium tuberculosis infected macrophages: a potential novel mechanism of immune evasion by Mycobacterium tuberculosis? Inflammation (1999) 0.92
Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism. J Neurosurg (2002) 0.92
Pancreatic ductal adenocarcinoma: a review of immunologic aspects. J Investig Med (2012) 0.91
Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape. Nat Rev Clin Oncol (2016) 0.91
A portrait of the Bcl-2 protein family: life, death, and the whole picture. J Clin Immunol (1999) 0.90
The fas and fas ligand pathways in liver allograft tolerance. Clin Exp Immunol (1999) 0.89
Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am J Pathol (1998) 0.89
Expression of costimulatory molecules in low-grade mucosa-associated lymphoid tissue-type lymphomas in vivo. Am J Pathol (1999) 0.88
Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation. Br J Cancer (2001) 0.88
Proteasome regulation of activation-induced T cell death. Proc Natl Acad Sci U S A (1997) 0.88
Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells. Br J Cancer (2000) 0.88
Fas and Fas-ligand expression in human pancreatic cancer. Ann Surg (2000) 0.88
Tissue microarray analysis of Fas and FasL expressions in human non-small cell lung carcinomas; with reference to the p53 and bcl-2 overexpressions. J Korean Med Sci (2005) 0.88
Breast cancer metastasis suppressor 1 regulates hepatocellular carcinoma cell apoptosis via suppressing osteopontin expression. PLoS One (2012) 0.87
Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells. Immunology (2002) 0.87
Soluble Fas ligand inhibits angiogenesis in rheumatoid arthritis. Arthritis Res Ther (2007) 0.86
Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. Am J Pathol (2003) 0.86
CD95 ligand expression as a mechanism of immune escape in breast cancer. Immunology (2000) 0.86
Sunlight-induced basal cell carcinoma tumor cells and ultraviolet-B-irradiated psoriatic plaques express Fas ligand (CD95L). J Clin Invest (1998) 0.86
Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. Br J Cancer (2000) 0.86
Fas ligand and immune evasion. Nat Med (1996) 0.86
Prognostic significance of RCAS1 expression in relation to the infiltration of dendritic cells and lymphocytes in patients with esophageal carcinoma. Dig Dis Sci (2007) 0.86
New cellular tools reveal complex epithelial-mesenchymal interactions in hepatocarcinogenesis. Br J Cancer (2008) 0.85
Biological treatment for liver tumor and new potential biomarkers. Dig Dis Sci (2007) 0.85
Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide. J Clin Invest (1997) 0.84
Association of the polymorphisms in the Fas/FasL promoter regions with cancer susceptibility: a systematic review and meta-analysis of 52 studies. PLoS One (2014) 0.84
FADD adaptor in cancer. Med Immunol (2005) 0.84
CD54 expression is predictive for lymphatic spread in human gastric carcinoma. Dig Dis Sci (2005) 0.84
FAS and FASLG genetic variants and risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev (2010) 0.84
Application of a Fas ligand encoding a recombinant adenovirus vector for prolongation of transgene expression. J Virol (1998) 0.83
Apoptotic variants as predictors of risk of oropharyngeal cancer recurrence after definitive radiotherapy. Int J Cancer (2015) 0.83
Expression of RCAS1 and FasL in human trophoblasts and uterine glands during pregnancy: the possible role in immune privilege. Clin Exp Immunol (2001) 0.83
Bornyl caffeate induces apoptosis in human breast cancer MCF-7 cells via the ROS- and JNK-mediated pathways. Acta Pharmacol Sin (2013) 0.83
FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex. Cell (1996) 12.07
Two CD95 (APO-1/Fas) signaling pathways. EMBO J (1998) 10.42
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) Nature (1995) 8.23
Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science (1989) 7.76
Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J (1995) 7.60
Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976. J Biol Chem (1993) 7.16
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature (1997) 6.23
Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J Neurochem (1979) 5.92
The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J (1999) 5.47
The hydrogen hypothesis for the first eukaryote. Nature (1998) 5.26
Sequence and analysis of chromosome 4 of the plant Arabidopsis thaliana. Nature (1999) 5.03
Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature (1995) 4.95
The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene (2007) 4.90
Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell (1998) 4.77
The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ (2003) 4.72
Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J (1995) 4.68
A modified procedure for the rapid preparation of efficiently transporting vesicles from small intestinal brush border membranes. Their use in investigating some properties of D-glucose and choline transport systems. Biochim Biophys Acta (1978) 4.66
Increased expression of Ia antigens on resting B cells: an additional role for B-cell growth factor. Proc Natl Acad Sci U S A (1984) 4.62
FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J (1997) 4.56
T cell-derived B cell differentiation factor(s). Effect on the isotype switch of murine B cells. J Exp Med (1982) 4.51
Serological, biochemical, and functional identity of B cell-stimulatory factor 1 and B cell differentiation factor for IgG1. J Exp Med (1985) 4.47
The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med (2002) 4.47
T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J Exp Med (1992) 4.31
Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway. Nature (1993) 4.20
Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature (1995) 4.20
The structure of the Antennapedia homeodomain determined by NMR spectroscopy in solution: comparison with prokaryotic repressors. Cell (1989) 4.13
Long-term survival in patients with hereditary hemochromatosis. Gastroenterology (1996) 4.00
Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci (2004) 3.86
High-frequency mutagenesis of human cells and characterization of a mutant unresponsive to both alpha and gamma interferons. Proc Natl Acad Sci U S A (1991) 3.83
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res (1996) 3.77
Lysosomes of the arterial wall. I. Isolation and subcellular fractionation of cells from normal rabbit aorta. J Exp Med (1972) 3.73
Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med (1985) 3.73
FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem (1996) 3.72
Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet (2001) 3.62
Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature (1995) 3.59
Protein--DNA contacts in the structure of a homeodomain--DNA complex determined by nuclear magnetic resonance spectroscopy in solution. EMBO J (1990) 3.50
The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem (1999) 3.32
Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med (1995) 3.20
Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol (2008) 3.18
Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest (1993) 3.13
A small animal model of human Helicobacter pylori active chronic gastritis. Gastroenterology (1990) 3.03
FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity (2000) 2.99
The interaction with DNA of wild-type and mutant fushi tarazu homeodomains. EMBO J (1990) 2.97
Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem (2001) 2.94
p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med (1998) 2.91
Hydrogenosome, a cytoplasmic organelle of the anaerobic flagellate Tritrichomonas foetus, and its role in pyruvate metabolism. J Biol Chem (1973) 2.90
Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol (1990) 2.72
Mathematical modeling reveals threshold mechanism in CD95-induced apoptosis. J Cell Biol (2004) 2.70
Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med (1996) 2.65
Helicobacter mustelae-associated gastritis in ferrets. An animal model of Helicobacter pylori gastritis in humans. Gastroenterology (1990) 2.64
Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology (1999) 2.61
DNA binding properties of the purified Antennapedia homeodomain. Proc Natl Acad Sci U S A (1990) 2.60
A novel sec-independent periplasmic protein translocation pathway in Escherichia coli. EMBO J (1998) 2.57
Role of tissue factor in embryonic blood vessel development. Nature (1996) 2.54
Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study. Gut (2006) 2.53
Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J Biol Chem (1999) 2.52
Universal digital quantum simulation with trapped ions. Science (2011) 2.49
In vitro translocation of bacterial proteins across the plasma membrane of Escherichia coli. Proc Natl Acad Sci U S A (1984) 2.46
Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol (1993) 2.45
Nuclear magnetic resonance solution structure of the fushi tarazu homeodomain from Drosophila and comparison with the Antennapedia homeodomain. J Mol Biol (1994) 2.43
Macrolide-induced Churg-Strauss syndrome in a patient with atopy. Lancet (1997) 2.42
B-cell growth factor (B-cell growth factor I or B-cell-stimulating factor, provisional 1) is a differentiation factor for resting B cells and may not induce cell growth. Proc Natl Acad Sci U S A (1985) 2.41
FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol (2001) 2.39
Lymphocytic and granulomatous hypophysitis: experience with nine cases. Neurosurgery (1997) 2.37
Protein export in Escherichia coli requires a soluble activity. Proc Natl Acad Sci U S A (1984) 2.34
Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest (1997) 2.32
Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res (1997) 2.32
Vacuolating cytotoxin of Helicobacter pylori plays a role during colonization in a mouse model of infection. Infect Immun (2001) 2.30
Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest (1994) 2.30
In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy. Gut (2005) 2.30
FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J Biol Chem (1997) 2.29
Structure of the Abelson murine leukemia virus genome. Cell (1979) 2.27
Diversity of Helicobacter pylori vacA and cagA genes and relationship to VacA and CagA protein expression, cytotoxin production, and associated diseases. J Clin Microbiol (1998) 2.26
TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ (2005) 2.25
In vivo molecular imaging with cetuximab, an anti-EGFR antibody, for prediction of response in xenograft models of human colorectal cancer. Endoscopy (2013) 2.25
Perforation of the esophagus after dilation treatment for dysphagia in a patient with eosinophilic esophagitis. Endoscopy (2006) 2.24
Determination of the nuclear magnetic resonance solution structure of an Antennapedia homeodomain-DNA complex. J Mol Biol (1993) 2.20
Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity (2000) 2.17
Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis. Aliment Pharmacol Ther (2014) 2.15
Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther (1994) 2.14
Risk of infection with Helicobacter pylori and hepatitis A virus in different groups of hospital workers. Am J Gastroenterol (1997) 2.09
Proviral load determination of different feline immunodeficiency virus isolates using real-time polymerase chain reaction: influence of mismatches on quantification. Electrophoresis (1999) 2.09
Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ (2001) 2.08
Three metronidazole-resistant strains of Trichomonas vaginalis from the United States. Am J Obstet Gynecol (1980) 2.06
Divergent signalling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death. EMBO J (1994) 2.05
Specific binding of alloantigens to T cells activated in the mixed lymphocyte reaction. J Exp Med (1976) 2.04